Andrew Hopkins

Andrew Hopkins founded Exscientia and developed the first AI-designed drug molecules to enter human clinical trials, demonstrating that AI-driven molecular design can produce clinical candidates for oncology with improved properties and reduced development timelines. His platform combines automated chemical synthesis with AI-guided design-make-test-analyze cycles that iteratively optimize drug candidates. He has applied AI to clinical trial design, using machine learning for patient stratification and adaptive trial protocols that improve success rates in oncology studies. His company's pipeline includes multiple AI-designed cancer drug candidates in clinical development, providing real-world validation of the AI drug discovery approach.